| Trial ID: | L3032 |
| Source ID: | NCT01536626
|
| Associated Drug: |
Biphasic Insulin Aspart 30
|
| Title: |
Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands
|
| Acronym: |
SWITCH
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: biphasic insulin aspart 30
|
| Outcome Measures: |
Primary: HbA1c (glycosylated haemoglobin) | Secondary: Number of hypoglycaemic events|Treatment satisfaction: ITSQ (Insulin Treatment Satisfaction Questionnaire)|Quality of Life (QoL) using the World Health Organization Wellbeing Index (WHO-5)
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
211
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2006-06-09
|
| Completion Date: |
2007-04-10
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-24
|
| Locations: |
Novo Nordisk Investigational Site, Alphen a/d Rijn, Netherlands
|
| URL: |
https://clinicaltrials.gov/show/NCT01536626
|
